Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622507 | 0.98 | EPHX1 (0.42) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL305826 | 0.98 | EPHX1 (0.42) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL9669443 | 0.96 | EPHX1 (0.35) | EPHX1CYP19A1NAAAHTTCYP2C19 | |
| SCHEMBL3483069 | 0.83 | EPHX1 (0.41) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL305167 | 0.83 | EPHX1 (0.40) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL6578556 | 0.83 | KAT2B (0.35) | TSHRHPGDNPSR1 | |
| Cilexetil SCHEMBL3483374 | 0.82 | EPHX1 (0.44) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL16731836 | 0.82 | EPHX1 (0.44) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL12603500 | 0.82 | EPHX1 (0.42) | EPHX1CYP19A1NAAAHTTCA12 | |
| SCHEMBL8857471 | 0.80 | EPHX1 (0.39) | EPHX1CYP19A1NAAAHTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1437352-A1 | BENZIMIDAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0337637-B1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | SANKYO CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0597821-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0482657-A2 | Cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-29 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | EPHX1 3070/4885CYP19A1 1168/4885NAAA 96/4885 |
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | SI, MLNR, FABP2 | EPHX1 3777/4885CYP19A1 3081/4885NAAA 1956/4885 |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | EPHX1 4523/4885CYP19A1 3233/4885NAAA 985/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | EPHX1 3070/4885CYP19A1 1168/4885NAAA 96/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | EPHX1 3352/4885CYP19A1 2968/4885NAAA 44/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | EPHX1 3262/4885CYP19A1 1110/4885NAAA 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.